A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01525394 |
Recruitment Status
:
Completed
First Posted
: February 2, 2012
Last Update Posted
: March 4, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Refractory Solid Tumors Lymphomas | Drug: Lenvatinib Drug: Moxifloxacin 400 mg Drug: Placebos (matched to 4 mg and 10 mg lenvatinib capsules). | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 52 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval |
Study Start Date : | December 2010 |
Actual Primary Completion Date : | August 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: Lenvatinib Capsules |
Drug: Lenvatinib
32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
Other Name: E7080
|
Active Comparator: Moxifloxacin tablets |
Drug: Moxifloxacin 400 mg
Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
|
Placebo Comparator: Placebos |
Drug: Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
|
- To evaluate the potential for QT/QTc prolongation by 32 mg lenvatinib using a placebo control and moxifloxacin as the positive control. [ Time Frame: 2 months ]
- To evaluate the safety of lenvatinib in healthy subjects. [ Time Frame: 2 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Subjects must meet all of the following criteria to be included in this study:
- Normal, healthy male and female subjects greater than or equal to 18 years of age at the time of informed consent.
- All females must have a negative serum human chorionic gonadotropin (hCG) pregnancy test result at Screening and Baseline. Females of child-bearing potential must agree to use a medically acceptable method of contraception (e.g., abstinence, an intrauterine device (IUD), a double-barrier method such as condom + spermicide or condom + diaphragm with spermicide, a contraceptive implant, an oral contraceptive or have a vasectomized partner) throughout the entire study period and for 30 days after study drug discontinuation. The only subjects who will be exempt from this requirement are postmenopausal women (defined as greater than age 50 and at least 12 months of amenorrhea) or subjects who have been sterilized surgically or who are otherwise proven sterile (e.g., bilateral tubal ligation with surgery at least 6 months prior to dosing, hysterectomy, or bilateral oophorectomy with surgery at least 2 months prior to dosing). All women who are of reproductive potential and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 12 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
- Male patients who are not abstinent or have undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly affective method of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).
- Partners of male and female subjects must use an effective method of contraception (e.g., barrier method, IUD), commencing prior to or at initiation of study drug and continuing for the duration of the study and for 30 days after study drug discontinuation. All females who are of reproductive potential and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 12 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
- Voluntarily provide written informed consent prior to any study procedures.
- Are willing and able to comply with all aspects of the protocol for the duration of the study.
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from participation in the study:
- Subjects with any clinically significant abnormality, including a QTc interval of greater than 450 msec, on 12-lead ECG at the time of the Screening Period, Baseline Periods, or 30 minutes before administration of study drug.
- A history of myocardial infarction, syncope or cardiac arrhythmias.
- A history of uncontrolled hypertension, defined as a systolic pressure of greater than 140 mm Hg and diastolic pressure of greater than 90 mm Hg.
- A history of unstable heart disease or additional risk factors for Torsades de Pointes (TdP) including heart failure, hypokalemia, or a family history of congenital long QT syndrome or unexplained cardiac arrest.
- Subjects with a history of gastrointestinal surgery (hepatectomy, nephrotomy, digestive organ resection, etc.) that may affect PK profiles of lenvatinib.
- Known intolerance to the study drug or moxifloxacin (Avelox) (or any of the excipients).
- A positive result from human immunodeficiency virus (HIV), hepatitis A antibody (HAVAb), hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb) tests at Screening.
- A known or suspected history of drug or alcohol misuse within 6 months prior to Screening, or who have a positive urine drug test or breath alcohol test at Screening.
- Subjects who participated in another clinical trial of an investigational drug or device within 4 weeks prior to dosing.
- Subjects who received blood products within 4 weeks, or donated blood within 8 weeks, or donated plasma within one week of dosing.
- Subjects who have engaged in heavy exercise within 2 weeks prior to check-in (e.g., marathon runners, weight lifters, etc.).
- Females who are pregnant or breastfeeding.
- Subjects who are unwilling or unable to abide by the requirements of the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01525394
United States, Washington | |
Charles River | |
Tacoma, Washington, United States, 98418 |
Study Director: | Robert Shumaker | Eisai Inc. |
Responsible Party: | Eisai Inc. |
ClinicalTrials.gov Identifier: | NCT01525394 History of Changes |
Other Study ID Numbers: |
E7080-A001-002 |
First Posted: | February 2, 2012 Key Record Dates |
Last Update Posted: | March 4, 2015 |
Last Verified: | April 2012 |
Keywords provided by Eisai Inc.:
lymphomas Refractory solid tumors |
Additional relevant MeSH terms:
Moxifloxacin Fluoroquinolones Lenvatinib Norgestimate, ethinyl estradiol drug combination Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Antineoplastic Agents Contraceptives, Oral, Combined Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Nucleic Acid Synthesis Inhibitors Protein Kinase Inhibitors |